Bright Minds Biosciences Inc., often referred to as BRIGHT MINDS BIOSCIENCES INC., operates in the biotechnology industry, with a focus on developing therapeutics to enhance the lives of patients with severe and life-altering diseases. The company was established on May 31, 2
No pros available.
No cons available.
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | SMMT | Summit Therapeutics Inc. | 1,349.40 Bn | -1,464.17 | 0.00 | 0.01 Bn |
| 2 | ONC | BeOne Medicines Ltd. | 437.43 Bn | 6,381.20 | 87.97 | 1.90 Bn |
| 3 | VRTX | Vertex Pharmaceuticals Inc / Ma | 116.09 Bn | 31.59 | 9.90 | 1.83 Bn |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | 78.10 Bn | 17.06 | 5.48 | 2.71 Bn |
| 5 | ALNY | Alnylam Pharmaceuticals, Inc. | 55.87 Bn | 1,282.42 | 17.40 | 3.21 Bn |
| 6 | ARGX | Argenx Se | 52.85 Bn | 35.08 | 27,559.65 | - |
| 7 | BNTC | Benitec Biopharma Inc. | 41.75 Bn | -998.33 | 0.00 | 0.00 Bn |
| 8 | INSM | INSMED Inc | 37.80 Bn | -31.93 | 84.56 | 0.74 Bn |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| EV to Assets | 12.79 | 12.31 | |
| EV to Cash from Ops. | -85.15 | 23.25 | |
| EV to Debt | 10,685.96 | 738.44 | |
| EV to EBIT | -73.19 | -9.16 | |
| EV to EBITDA | -74.73 | 6.95 | |
| EV to Free Cash Flow [EV/FCF] | -85.15 | 21.90 | |
| EV to Market Cap | 0.86 | 65.67 | |
| EV to Revenue | 0.00 | 227.32 | |
| Price to Book Value [P/B] | 15.03 | 22.34 | |
| Price to Earnings [P/E] | -87.38 | -11.77 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Dividend Coverage Ratio | 0.00 | -11.94 | |
| Dividend Payout Ratio % | 0.00 | 0.16 | |
| Dividend per Basic Share | 0.00 | 0.01 | |
| FCF Dividend Payout Ratio % | 0.00 | -0.14 | |
| Interest Coverage | 0.00 | 841.00 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Capex Growth (1y) % | 0.00 | -27.13 | |
| Cash and Equivalents Growth (1y) % | 730.14 | 734.65 | |
| Dividend Growth (1y) % | 0.00 | 0.01 | |
| EBIAT Growth (1y) % | -150.73 | -46.93 | |
| EBITDA Growth (1y) % | -150.72 | -1.68 | |
| EBIT Growth (1y) % | -157.98 | -56.45 | |
| EBT Growth (1y) % | -157.98 | -12.70 | |
| EPS Growth (1y) % | -43.48 | -28.31 | |
| FCF Growth (1y) % | -205.15 | -31.90 | |
| Gross Profit Growth (1y) % | 0.00 | 226.84 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Asset Utilization Ratio | 0.00 | 0.14 | |
| Cash Payout Ratio | 0.00 | 0.00 | |
| Cash Ratio | 84.94 | 3.85 | |
| Current Ratio | 86.56 | 7.27 | |
| Debt to Equity Ratio | 0.00 | 0.40 | |
| Interest Cover Ratio | 0.00 | 841.00 | |
| Times Interest Earned | 0.00 | 841.00 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| EBITDA Margin % | 0.00 | -18,234.31 | |
| EBIT Margin % | 0.00 | -18,580.80 | |
| EBT Margin % | 0.00 | -19,488.74 | |
| Gross Margin % | 0.00 | -7.59 | |
| Net Profit Margin % | 0.00 | -19,439.22 |